As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the...

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

March 7, 2024 During the latter part of 2023 and following notification by the World Health Organization that B/Yamagata lineage viruses have not been confirmed as detected in circulation since...

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

CSL Seqirus presents new data at the 9th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world.1,2 The French data highlights how vaccines...

SUMMIT, N.J., September 15, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today announced new data that will be presented at the European Scientific Working Group on Influenza (ESWI)...

CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a...

Melbourne, Monday 22 May CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping...

Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more...

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing...

CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in...

Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute. Under the partnership, Seqirus will participate in research projects and knowledge generation around both the threat of seasonal influenza and the development of innovative approaches to pandemic preparedness and response.

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response...

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for...

Summit, NJ, USA 07 Dec 2021 Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the relative...

Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...

• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...

• Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Summit, NJ, USA 19 Aug...

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...

This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...

Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...

11 Dec 2020 The University of Queensland (UQ) and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and...

16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...

This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...

Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...

GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY −Partnership brings together world-leading plasma companies to focus on developing and...

Safeguarding our people and communities remains our top priority. 03 Apr 2020 As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and...

This news release is intended for medical and pharmaceutical trade media and financial media only 31 Mar 2020 Seqirus, a global leader in influenza prevention, today announced that its adjuvanted...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. By Anthony Farina – Chief Communications Officer, CSL Limited | 23 Mar 2020...

Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit. 23 Sep 2019 Seqirus, a global leader in influenza prevention, has...

This news release is intended for Health Professional media only. 17 Sep 2019 Seqirus, a global leader in influenza prevention, and Laboratoire Arrow, a fast growing player in the pharmaceutical...

This news release is intended for Health Professional media only. Maidenhead, 5 September 2019 Seqirus, a global leader in influenza prevention, announced today that it has started on-time...

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating...

Summit, NJ – August 30, 2019 Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical...

Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of...

Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena. Monteriggioni (SI), July 19, 2019 Seqirus, a global...

This news release is intended for business and trade media only. Summit, New Jersey 15 Jul 2019 Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming...

This news release is intended for Health Professional media only. Seqirus to launch its cell-based influenza vaccine in Europe for the 2019-20 season Real-world data indicates cell-based influenza...

This news release is intended for Health Professional media only. 16 Nov 2018 Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that...

The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. 16 Nov 2018 Seqirus, a...

Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season. 19 Oct 2018 Seqirus, a global leader in...

Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research New York, NY and Maidenhead, UK — 06/26/2018 The Human Vaccines Project, a nonprofit public-private...

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management...

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...

This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. 08 Nov 2017 New fill-and-finish facility...

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase...

Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. 20 Jul 2017 Seqirus is now...

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather...

Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. 25 Feb 2017 The company, which is part of global...